NCT05493124|UnknownEarly Phase 1
Loading search results
Sponsor study identifier
interventional
180
1 country
3
Study Start
July 1, 2021
Actual (reported)Primary Completion
December 31, 2023
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
December 31, 2023
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
To explore the efficacy and safety of "Manpixiao" in the treatment of Chronic Atrophic Gastritis.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 31, 2023
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
July 1, 2021
Actual (reported)July 29, 2022
Actual (reported)August 9, 2022
Actual (reported)December 31, 2023
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
December 31, 2023
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Pathological improvement rate of gastric mucosa
Pathological diagnosis of gastric mucosal tissue samples obtained by gastroscopy
The enrollment inspection shall be completed within one month before enrollment; The examination after treatment should be carried out within 1 month after the completion of treatment.
Gastric mucosal status under gastroscope
The enrollment inspection shall be completed within one month before enrollment; The examination after treatment should be carried out within 1 month after the completion of treatment.
Score of main symptoms of stomach system
They were evaluated on the day of enrollment and the day of the end of the treatment process
A traditional Chinese medicine composition (has applied for Chinese patent)，Take 17.15g daily, twice in the morning and evening, for a total of 24 weeks
Including treated with Chinese patent drugs such as Weifuchun and morodan, or treated with antacids, motivational drugs, gastric mucosal protectants, vitamins, folic acid, selenium containing preparations and other drugs. Take it according to the instructions.
A traditional Chinese medicine composition
Other drugs that may have therapeutic effects
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Dongfang Hospital, Beijing University of Chinese Medicine
Beijing, China
Dongzhimen Hospital, Beijing University of TCM
Beijing, China
First Submitted
July 29, 2022
First Posted
August 9, 2022
Study Start
July 1, 2021
Actual (reported)Primary Completion
December 31, 2023
Estimated (date passed)Contact the study team to confirm eligibility.
Zaozhuang Hospital, Beijing University of Chinese Medicine
Beijing, China
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
December 31, 2023
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
August 9, 2022
Record last verified: 2021-09
Obtained by asking the first or correspondent author if necessary
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: